Brand-Name Drug Makers Blame Patent Expirations For Depressed Profits
Weaker earnings among many of the world's top drug makers have raised questions about the blockbuster drug model, as the industry faces an ominous wave of patent expirations over the next...To view the full article, register now.
Already a subscriber? Click here to view full article